Original Article

Journal of Investigative Dermatology (1994) 102, 967–969; doi:10.1111/1523-1747.ep12384205

Patient Measurement of Psoriasis Disease Severity with a Structured Instrument

Alan B Fleischer Jr, Stephen R Rapp, David M Reboussin, Jill C Vanarthos and Steven R Feldman

Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina, U.S.A.

Received 1 September 1993; Accepted 18 January 1994.

Top

Abstract

The Psoriasis Area and Severity Index (PASI) is used by dermatologic investigators to assess psoriasis disease severity. PASI measures are time-consuming and require trained personnel. We developed and evaluated a structured PASI-like instrument for self-measurement of psoriasis disease severity for use in future large-scale epidemiologic studies. The instrument consisted of a silhouette of a body for patients to shade in affected areas and of three modified visual analog scales for recording the redness, thickness, and scaliness of an average lesion. The resulting "patient PASI" score was compared to investigator PASI measurements in 43 patients with mild to severe psoriasis. Patients and investigator also recorded a subjective global severity score. The patient PASI score was highly predictive of the investigator PASI score (r2 = 0.71, p < 0.0001) and the investigator global score (r2 = 0.37, p < 0.0001). The patient global score was also predictive of the investigator PASI (r2 = 0.18, p < 0.0053) and the investigator global score (r2 = 0.10, p < 0.044), but these relationships exhibit wide predicted confidence intervals. Following the initial evaluation by 18.4 plusminus 9.1 d of therapy, one-way t tests for paired samples (pre and post) showed significant improvements in the patient PASI (p < 0.003) and investigator PASI (p < 0.05). We conclude that although patients' overall scores may not allow for accurate prediction of clinical disease severity in a single individual, this structured instrument facilitates prediction of psoriasis disease severity in a population.

Keywords:

Psoriasis Area and Severity Index (PASI), structured instrument, psoriasis

Top

References

  1. Fredriksson, T, Pettersson, U: Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157: 238–244, 1978 | PubMed | ISI | ChemPort |
  2. Harland, CC, Whitaker, RP, Barron, JL, Holden, CA: Increased urine neopterin levels in psoriasis. Br J Dermatol 127: 453–457, 1992
  3. Cecchi, R, Seghieri, G, Gironi, A, Tuci, F, Giomi, A: Relationship between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology 185: 93–95, 1992
  4. Collins, P, Rogers, S: Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 127: 392–395, 1992
  5. Lauharanta, J, Geiger, JM: A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 121: 107–112, 1989
  6. Marks, R, Barton, SP: Assessment of disease progress in psoriasis. Arch Dermatol 125: 235–240, 1989 | Article | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT